title: Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
authors.affiliation: Robert H. Laurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.affiliation: Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Horwitz
authors.affiliation: Center for Blood Cell Therapies, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.affiliation: Yale Cancer Center, Yale Medical Group, New Haven, CT, USA.
authors.forename: Francine M
authors.initials: FM
authors.lastname: Foss
authors.affiliation: Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
authors.forename: Lubomir
authors.initials: L
authors.lastname: Sokol
authors.affiliation: Department of Hematology, Royal North Shore Hospital, St Leonards, NSW, Australia.
authors.forename: Matthew
authors.initials: M
authors.lastname: Greenwood
authors.affiliation: Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: Dolores
authors.initials: D
authors.lastname: Caballero
authors.affiliation: Hematology, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Morschhauser
authors.affiliation: Paracelsus Medical University, Klinikum Nuernberg, Nuernberg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Wilhelm
authors.affiliation: Houston Methodist Cancer Center, Houston, TX, USA.
authors.forename: Swaminathan Padmanabhan
authors.initials: SP
authors.lastname: Iyer
authors.affiliation: Clinical Research Division, University of Washington, Seattle, WA, USA.
authors.forename: Andrei R
authors.initials: AR
authors.lastname: Shustov
authors.affiliation: Veristat, LLC, Southborough, MA, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Wolfson
authors.affiliation: Veristat, LLC, Southborough, MA, USA.
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Balser
authors.affiliation: Hospices Civils de Lyon, University of Lyon, Pierre-Benite, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D000368:Aged; D047630:Depsipeptides / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate
chemical_list: D047630:Depsipeptides; C087123:romidepsin